Jing Chao1, Katya B Rubinow1, Mario Kratz1, John K Amory1, Alvin M Matsumoto1, Stephanie T Page1. 1. Center for Research in Reproduction and Contraception (J.C., K.B.R., S.T.P., J.K.A.) and Diabetes Institute, Division of Metabolism, Endocrinology, and Nutrition (K.B.R. and S.T.P.) and Division of Gerontology & Geriatric Medicine (A.M.M.), Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98195; The Fred Hutchinson Cancer Research Center (M.K.); and the Geriatric Research, Education and Clinical Center (A.M.M.), VA Puget Sound Health Care System, Seattle, Washington 98108.
Abstract
CONTEXT: T deprivation increases risk of insulin resistance in men, but whether this risk is independent of changes in body composition is unknown. Further, the metabolic roles of T and its metabolite estradiol have not been clearly defined in men. OBJECTIVE: This study sought to establish the effects of selective sex steroid withdrawal on insulin sensitivity in healthy men. DESIGN, SETTING, AND PARTICIPANTS: This was a double-blinded, placebo-controlled, randomized trial at an academic medical center of 56 healthy men, 19-55 years of age. INTERVENTIONS: Subjects received the GnRH antagonist acyline plus one of the following: placebo gel (Castrate), 1.25 g testosterone gel (Low T/E), 5 g testosterone gel (Normal T/E), or 5 g testosterone gel with letrozole (Normal T/Low E) daily for 4 weeks. Body composition and glucose tolerance were assessed at baseline and end of treatment. MAIN OUTCOME MEASURE: Insulin sensitivity was quantified by the Matsuda index. RESULTS: Predicted circulating sex steroid concentrations were achieved in all treatment groups. The time-by-group interaction for Matsuda index did not achieve significance in overall repeated measures ANOVA (baseline vs week 4; P = .16). A significant time-by-group interaction was observed for fat mass (P = .003), with changes in fat mass attributable predominantly to estrogen exposure in linear regression analysis (P = .016). A time-by-group interaction also was observed for lean mass (P = .03) and influenced by androgen exposure (P = .003). CONCLUSIONS: Short-term sex steroid withdrawal in healthy men causes adverse changes in body composition. These findings support the role of estradiol as a determinant of adiposity in men.
RCT Entities:
CONTEXT: T deprivation increases risk of insulin resistance in men, but whether this risk is independent of changes in body composition is unknown. Further, the metabolic roles of T and its metabolite estradiol have not been clearly defined in men. OBJECTIVE: This study sought to establish the effects of selective sex steroid withdrawal on insulin sensitivity in healthy men. DESIGN, SETTING, AND PARTICIPANTS: This was a double-blinded, placebo-controlled, randomized trial at an academic medical center of 56 healthy men, 19-55 years of age. INTERVENTIONS: Subjects received the GnRH antagonist acyline plus one of the following: placebo gel (Castrate), 1.25 g testosterone gel (Low T/E), 5 g testosterone gel (Normal T/E), or 5 g testosterone gel with letrozole (Normal T/Low E) daily for 4 weeks. Body composition and glucose tolerance were assessed at baseline and end of treatment. MAIN OUTCOME MEASURE: Insulin sensitivity was quantified by the Matsuda index. RESULTS: Predicted circulating sex steroid concentrations were achieved in all treatment groups. The time-by-group interaction for Matsuda index did not achieve significance in overall repeated measures ANOVA (baseline vs week 4; P = .16). A significant time-by-group interaction was observed for fat mass (P = .003), with changes in fat mass attributable predominantly to estrogen exposure in linear regression analysis (P = .016). A time-by-group interaction also was observed for lean mass (P = .03) and influenced by androgen exposure (P = .003). CONCLUSIONS: Short-term sex steroid withdrawal in healthy men causes adverse changes in body composition. These findings support the role of estradiol as a determinant of adiposity in men.
Authors: D Simon; M A Charles; N Lahlou; K Nahoul; J M Oppert; M Gouault-Heilmann; N Lemort; N Thibult; E Joubert; B Balkau; E Eschwege Journal: Diabetes Care Date: 2001-12 Impact factor: 19.112
Authors: Joel S Finkelstein; Hang Lee; Sherri-Ann M Burnett-Bowie; J Carl Pallais; Elaine W Yu; Lawrence F Borges; Brent F Jones; Christopher V Barry; Kendra E Wulczyn; Bijoy J Thomas; Benjamin Z Leder Journal: N Engl J Med Date: 2013-09-12 Impact factor: 91.245
Authors: J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies Journal: J Clin Endocrinol Metab Date: 2001-09 Impact factor: 5.958
Authors: Maria A Yialamas; Andrew A Dwyer; Erin Hanley; Hang Lee; Nelly Pitteloud; Frances J Hayes Journal: J Clin Endocrinol Metab Date: 2007-08-28 Impact factor: 5.958
Authors: Kristina M Utzschneider; Ronald L Prigeon; Mirjam V Faulenbach; Jenny Tong; Darcy B Carr; Edward J Boyko; Donna L Leonetti; Marguerite J McNeely; Wilfred Y Fujimoto; Steven E Kahn Journal: Diabetes Care Date: 2008-10-28 Impact factor: 19.112
Authors: Katya B Rubinow; Jing H Chao; Derek Hagman; Mario Kratz; Brian Van Yserloo; Nilesh W Gaikwad; John K Amory; Stephanie T Page Journal: Am J Physiol Endocrinol Metab Date: 2017-07-11 Impact factor: 4.310
Authors: Natalie J Nokoff; Sharon L Scarbro; Kerrie L Moreau; Philip Zeitler; Kristen J Nadeau; Daniel Reirden; Elizabeth Juarez-Colunga; Megan M Kelsey Journal: Transgend Health Date: 2021-04-16
Authors: Prachi Singh; Naima Covassin; Fatima H Sert-Kuniyoshi; Kara L Marlatt; Abel Romero-Corral; Diane E Davison; Ravinder J Singh; Michael D Jensen; Virend K Somers Journal: Physiol Rep Date: 2021-12